Related Experiment Videos
Intravenous methylprednisolone efficacy in status asthmaticus of childhood
Insights
Intravenous methylprednisolone significantly improved clinical scores and lung function in children with status asthmaticus. This corticosteroid treatment also reduced asthma relapse rates within four weeks of discharge.
Area of Science:
- Pediatric Pulmonology
- Critical Care Medicine
- Pharmacology
Background:
- Status asthmaticus is a severe form of asthma exacerbation requiring hospitalization.
- Prompt and effective treatment is crucial to prevent long-term complications and reduce healthcare burden.
Purpose of the Study:
- To evaluate the efficacy of intravenous methylprednisolone in nonsteroid-dependent children hospitalized with status asthmaticus.
- To assess the impact of methylprednisolone on clinical outcomes, pulmonary function, and relapse rates.
Main Methods:
- A randomized controlled trial involving 49 children with status asthmaticus.
- Patients received either intravenous methylprednisolone or placebo, alongside standard care (isoetharine inhalations, aminophylline infusion).
- Clinical scoring, serial bedside spirometry (FEF25-75, PEFR, FVC, FEV1), and 4-week relapse rates were assessed.
Main Results:
- Methylprednisolone treatment showed a greater improvement in the clinical scoring index at 24 hours compared to placebo.
- Patients receiving methylprednisolone experienced a more rapid recovery from peripheral airway obstruction, evidenced by significant improvement in FEF25-75 at 36 hours.
- No significant difference in hospital stay duration was observed, but placebo patients had a higher incidence of asthma relapse (8 vs. 2).
Conclusions:
- Intravenous methylprednisolone is beneficial in treating pediatric status asthmaticus.
- Corticosteroid therapy accelerates recovery from airway obstruction and reduces post-discharge relapse rates.
- Further research may explore optimal dosing and duration for improved length-of-stay outcomes.
Abstract:
Forty-nine nonsteroid-dependent children hospitalized with status asthmaticus were randomized to receive IV placebo or methylprednisolone treatment (1 mg/kg every six hours). All patients received nebulized isoetharine inhalations and continuous IV aminophylline infusion. Twenty-four hours after admission, the methylprednisolone-treated patients demonstrated a greater rate of improvement in their clinical scoring index than did placebo-treated children. However, the duration of hospital stay was not significantly shortened. Twenty-eight of the patients performed serial bedside spirometry at 0, 12, 24, and 36 hours after admission. The methyl-prednisolone-treated patients experienced a more rapid recovery from peripheral airway obstruction as measured by forced expiratory flow rate during 25% to 75% of forced vital capacity (FEF25-75). The magnitude and rate of improvement in FEF25-75 was significantly greater at 36 hours (P less than .05) and independent of changes in peak expiratory flow rate, forced vital capacity, or forced expiratory volume in the first second of forced vital capacity. Placebo-treated patients had a higher incidence of asthma relapse within 4 weeks of discharge (eight v two relapses, P less than .05). Findings of this study indicate that IV corticosteroid therapy is beneficial in treating pediatric status asthmaticus.